Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and 100% disease control rate in the squamous NSCLC cohort, with a median response duration of 12.9 months, and was well tolerated with manageable side effects. These promising results support ongoing Phase 2/3 trials, with a dose selection interim analysis expected in the second half of 2027. This combination could offer a new outpatient treatment option for advanced NSCLC patients.
Eikon Therapeutics' updated data on EIK1001 in lung cancer provides context for health sector performance. For readers following health stocks, here is Pluang's market snapshot as of Oct 26, 2026 16:51 WIB: out of 150 priced US health-sector stocks, 75 rose and 29 fell. Among notable movers, TVTX traded at USD 50.87 with a 1-day change of +1.64% and a typical hold time of 11 days, compared to TAK at USD 20.56 (+1.58%) and ABCL at USD 12.00 (+1.52%) with a notably longer hold time of 41 days.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
Bavarian Nordic A/S has repurchased shares totaling 964,213 at an average price of DKK 222.22, spending approximately DKK 214 million under its share buy-back program initiated on September 1, 2026. The program, set to run until October 30, 2026, aim...
